Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Debtor distribution data (CK92) - Nykredit Realkredit A/S
-
First sovereign gender bond issued by Iceland
-
OPEN Health and fusion announce partnership to deliver AI-powered healthcare communications
-
Danske Bank share buy-back programme: Transactions in week 25
-
Prepayments, Realkredit Danmark A/S
-
Managers’ transactions
-
Novotech Appoints Dr. Ian Braithwaite as Vice President, Global Project Management to Lead World-Class Clinical Program Operations
-
Changes of number of shares and votes in BioPorto A/S
-
Prepayments (CK93) - Totalkredit A/S
-
Prepayments (CK93) - Nykredit Realkredit A/S
-
Extraordinary General Meeting of Jyske Realkredit A/S
-
Data on debtor composition
-
Transactions in connection with share buyback programme
-
Replacement in bonds for new lending - Nykredit Realkredit A/S
-
Hi-View Corporate Update
-
Volt Lithium to Participate in Live Webinar on June 25
-
Allecra Therapeutics and Acino Sign Exclusive Licensing and Supply Agreement for Allecra’s Novel Antibiotic EXBLIFEP® in Gulf Cooperation Council countries and South Africa
-
Share buy-back programme - week 25
-
OKX Marketplace and Astra Nova Launch Giveaway of 500 SuperNova NFT Whitelist Spots and 50 Shards
-
DNA Plc: Change in DNA’s Board of Directors
-
Preliminary data on early redemptions (prepayments)
-
Exor Press Release - Periodic Report on the Buyback Program
-
Bedford Metals Expands Satellite Survey to Include Close Lake Uranium Project
-
Combined General Meeting 2024: Adoption of all resolutions by a large majority - Michel Sirat, appointed independent Director and designated Chairman of the Audit Committee
-
RIBER: Major order in Asia for a RIBER MBE 49 production system
-
Lleida.net's sales increase 9% in the first five months of 2024, reaching 7.93 million euros
-
First gene therapy for prevalent pathologies in neurology receives FDA IND clearance - EG 427 initiating first-in-human clinical study
-
Transaction in Own Shares
-
Share repurchase programme
-
PolTREG’s type-1 diabetes Treg cell therapy PTG-007 demonstrates long-term safety and efficacy for up to 12 years
-
BGHL (GBP): NAV(s)
-
BGHL (EUR): NAV(s)
-
OSE Immunotherapeutics Announces Commercial and Revenue Sharing Agreement in the Field of CAR T-cell Therapies
-
Avance Gas Holding Ltd: Presentation in relation to the Marine Money Conference in NY
-
Start of Day Message
-
Norsk Hydro: Hydro and Macquarie formally begin renewable energy partnership
-
Valneva Announces Health Canada Approval of the World’s First Chikungunya Vaccine, IXCHIQ®
-
AstriVax enters clinical phase with its novel vaccine platform technology
-
CoinShares Announces Successful Sale of FTX Claim
-
Corbion reports the progress of its € 20 million share buyback program 17 June – 21 June 2024
-
Roche launches new analytical units for cobas® pro integrated solutions delivering greater efficiency and capacity to laboratories
-
China's Hangzhou empowers urban development with world-class power supply reliability
-
China's Hangzhou empowers urban development with world-class power supply reliability
-
SALESFORCE ALERT: Bragar Eagel & Squire, P.C. is Investigating Salesforce, Inc. on Behalf of Salesforce Stockholders and Encourages Investors to Contact the Firm
-
NIKE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against NIKE, Inc. and Encourages Investors to Contact the Firm
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, and Fastly and Encourages Investors to Contact the Firm
-
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Globe Life Inc. f/k/a Torchmark Corporation Investors to Secure Counsel Before Important July 1 Deadline in Securities Class Action – GL
-
Southeast Asia EcoHack 2024 Brings Together Innovators for Virtual Environmental Challenge
-
ROSEN, LEADING INVESTOR COUNSEL, Encourages Equinix, Inc. Investors to Secure Counsel Before Important July 1 Deadline in Securities Class Action First Filed by the Firm – EQIX
-
Altimmune Presents Data from Phase 2 MOMENTUM Trial of Pemvidutide in Obesity during Oral Presentation at the American Diabetes Association’s 84th Scientific Sessions
